Loading…
MAIA Biotechnology, Inc. is projected to rise to $1.33 by 2027, a +7% move from its current price of $1.25. MAIA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.22 | $1.25 | $1.29 | +0.05% |
| Aug 6 | $1.20 | $1.25 | $1.30 | +0.10% |
| Aug 7 | $1.19 | $1.25 | $1.31 | +0.14% |
| Aug 8 | $1.18 | $1.25 | $1.32 | +0.19% |
| Aug 9 | $1.18 | $1.25 | $1.33 | +0.24% |
| Aug 10 | $1.17 | $1.25 | $1.34 | +0.29% |
| Aug 11 | $1.16 | $1.25 | $1.35 | +0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.16 | $1.25 | $1.35 | +0.34% |
| Week 2 | $1.13 | $1.26 | $1.40 | +0.68% |
| Week 3 | $1.11 | $1.26 | $1.44 | +1.02% |
| Week 4 | $1.09 | $1.27 | $1.47 | +1.36% |
| Week 5 | $1.08 | $1.27 | $1.50 | +1.70% |
| Week 6 | $1.06 | $1.28 | $1.53 | +2.04% |
| Week 7 | $1.05 | $1.28 | $1.56 | +2.39% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted immunotherapies for cancer. Its lead product Ateganosine is a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology, Inc. (MAIA) is a healthcare stock currently trading at $1.20 per share.
Its market capitalization is $72.96M and it is ranked 4346.
Forecasts project a path from a flat near-term view in 2026 to longer-term upside, with 2030 average price of $1.72 and a 2050 average price of $5.97, accompanied by a 2050 max of $11.19 and a 397.8% ROI. The forecast also shows intermediate years with rising averages, including 2029 average $1.47 (ROI 22.7%), 2040 average $2.80 (ROI 133.5%), and sustained bullish sentiment into 2031–2035 (average ranges around $1.81–$2.03 with ROIs from about 50.7% to 69.1%).
A major floor 17.6% below — a decisive break under it would weaken the trend.
The nearest floor, 4.0% below — buyers have tended to step in here.
The nearest ceiling, 18.4% above — a clean break opens room to run.
A major ceiling 27.2% above — clearing it would confirm fresh momentum.
Key MAIA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MAIA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.24 | Buy | $1.25 | Buy |
| MA 10 | $1.26 | Sell | $1.27 | Sell |
| MA 20 | $1.35 | Sell | $1.31 | Sell |
| MA 50 | $1.35 | Sell | $1.35 | Sell |
| MA 100 | $1.36 | Sell | $1.40 | Sell |
| MA 200 | $1.46 | Sell | $1.49 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.62 | Neutral |
| Stoch RSI (14) | 27.46 | Neutral |
| CCI (20) | -73.52 | Neutral |
| Williams %R (14) | -81.48 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -14.97 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 18.52 | Buy |
| TRIX (15) | -0.26 | Sell |
| Awesome (5,34) | -0.12 | Sell |
| Ultimate (7,14,28) | 38.31 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 1.22 | Buy |
| ADX (14) | 16.40 | Neutral |
| ATR (14) | 0.03 | Info |
The short-term technical picture is bearish.
RSI(14) is 40, with the 50-day simple moving average at $1.35 and the 200-day simple moving average at $1.47.
Support is at $1.20 and resistance at $1.48. The 30-day price range spans from a low of $0.9957 to a high of $1.45.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.20 | $1.25 | $1.65 | 0% | Neutral | |
| $1.06 | $1.33 | $1.77 | +7% | Neutral | |
| $0.9846 | $1.27 | $1.76 | +2% | Neutral | |
| $1.18 | $1.57 | $2.23 | +26% | Bullish | |
| $1.36 | $1.85 | $2.69 | +48% | Bullish | |
| $1.42 | $1.95 | $2.91 | +56% | Bullish | |
| $1.45 | $2.04 | $3.10 | +63% | Bullish | |
| $1.41 | $2.01 | $3.11 | +61% | Bullish | |
| $1.45 | $2.11 | $3.31 | +69% | Bullish | |
| $1.50 | $2.21 | $3.53 | +77% | Bullish | |
| $1.96 | $3.09 | $5.26 | +147% | Bullish | |
| $3.74 | $6.65 | $12.39 | +432% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.20 | $1.25 | $1.51 | +0.00% |
| September 2026 | $1.10 | $1.30 | $1.59 | +4.36% |
| October 2026 | $1.10 | $1.31 | $1.61 | +0.13% |
| November 2026 | $1.07 | $1.29 | $1.60 | -1.44% |
| December 2026 | $1.09 | $1.32 | $1.65 | +2.37% |
Click any year to see its month-by-month MAIA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
MAIA Biotechnology, Inc.'s 2026 outlook centres on $1.25, within a $1.20 to $1.65 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, MAIA could reach as high as $1.77, with a base case around $1.33 and support toward $1.06 — roughly +7% from $1.25. Price action looks broadly range-bound.
Expect MAIA to range from $0.9846 to $1.76 through 2028. The $1.27 average target implies a +2% move from current prices. That is -4% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The MAIA price prediction for 2029 points to an average of $1.57 (low $1.18, high $2.23) — a potential gain of +26% on today's $1.25. Momentum favours further upside here.
In 2030, MAIA is projected to trade between $1.36 and $2.69, averaging $1.85 — a potential gain of +48% from today's $1.25. That is up +18% on the projected 2029 average. Buyers look set to stay in control over this stretch.
MAIA Biotechnology, Inc.'s 2031 outlook centres on $1.95, within a $1.42 to $2.91 range. That is up +6% on the projected 2030 average. That marks a +56% change versus current levels. Momentum favours further upside here.
By 2032, MAIA could reach as high as $3.10, with a base case around $2.04 and support toward $1.45 — roughly +63% from $1.25. Buyers look set to stay in control over this stretch.
Expect MAIA to range from $1.41 to $3.11 through 2033. The $2.01 average target implies a +61% move from current prices. That is -1% versus the projected 2032 average. Momentum favours further upside here.
The MAIA price prediction for 2034 points to an average of $2.11 (low $1.45, high $3.31) — a potential gain of +69% on today's $1.25. Buyers look set to stay in control over this stretch.
In 2035, MAIA is projected to trade between $1.50 and $3.53, averaging $2.21 — a potential gain of +77% from today's $1.25. That is up +5% on the projected 2034 average. Momentum favours further upside here.
MAIA Biotechnology, Inc.'s 2040 outlook centres on $3.09, within a $1.96 to $5.26 range. That is up +40% on the projected 2035 average. That marks a +147% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, MAIA could reach as high as $12.39, with a base case around $6.65 and support toward $3.74 — roughly +432% from $1.25. Momentum favours further upside here.
Investing $1,000 in MAIA today (≈ 800 MAIA) could be worth
$5,318.01
+$4,318.01 (+432%) by 2050 · US Dollar
Based on the average projected MAIA price of $6.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MAIAwould be worth at today's price.
$1,000 invested in MAIA on Jul 31, 2025 (≈ 636.942654 MAIA) would be worth
$796.18
-$203.82 (-20.4%) today · 0.80× · US Dollar
Based on a MAIA entry price of $1.57 vs. today's $1.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.24 | $1,008.06 | +0.8% |
| 1 month ago | $1.43 | $874.13 | -12.6% |
| 3 months ago | $1.34 | $932.84 | -6.7% |
| 6 months ago | $1.94 | $644.33 | -35.6% |
| 1 year ago | $1.57 | $796.18 | -20.4% |
| All time (4.0y) ago | $4.46 | $280.27 | -72.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MAIA forecast.
Our base-case forecast reaches $2.50 around 2040.
Implied market cap at $2.50: $152M
Long-term forecasts point to a bullish trajectory from the late 2020s through 2030 and beyond. In 2030 the average price is projected at $1.72 with a 43% ROI, followed by 2031 at $1.81 (50.7%), 2032 at $1.89 (57.9%), 2033 at $1.85 (54.2%), 2034 at $1.93 (61.1%), and 2035 at $2.03 (69.1%).
Looking further ahead, 2040 shows an average price of $2.80 with a 133.5% ROI, while 2050 shows an average price of $5.97 with a 397.8% ROI and a max of $11.19.
These forecasts are estimates and not guarantees; outcomes depend on factors such as market conditions and clinical development progress, and the path could differ from the depicted averages and ROIs.
Tap a question to reveal the answer.
2030 forecast: average price $1.72 with ROI 43%; min $1.27, max $2.51.
Near-term sentiment is bearish, but long-term forecasts show rising averages and sizable ROIs (e.g., 2040 ROI 133.5% and 2050 ROI 397.8%). These are estimates, not guarantees.
Yes. The 2050 forecast lists an average price of $5.97 and a max of $11.19, indicating potential to reach around $5 as part of the long-term path.
Current price is $1.20. Market cap is $72.96M.
Bearish sentiment with RSI(14) = 40. SMA(50) = $1.35, SMA(200) = $1.47. Support at $1.20 and resistance at $1.48. 30-day range: $0.9957 to $1.45.
MAIA Biotechnology, Inc. Community Discussion
0Share your MAIA Biotechnology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.